Bristol-Myers selling Ireland plant to South Korean company with large aspirations

Fierce Pharma ------ Bristol-Myers Squibb, which is shifting its focus toward biologics manufacturing, will unload an API plant in Ireland to a South Korean company that has aspirations of becoming a big deal in contract manufacturing.The U.S. drugmaker said today that it will sell its plant in Swords to SK Biotek, a unit of South Korea’s third largest conglomerate, SK Holdings. SK has been a BMS ingredient supplier for a decade. The two kept terms under wraps except to say the deal should close in Q4 and that SK will continue to produce the products BMS now makes at the plant, which includes the API for Bristol-Myers Squibb and Pfizer’s anticoagulant Eliquis. SK Biotek will take on about 300 workers at the facility, while some will transfer to jobs in Dublin, a BMS spokesman said in an email. To learn more click on the picture below to read the article.